Characteristics and Clinical Value of 18F-FDG PET/CT in the Management of Adult-Onset Still's Disease: 35 Cases.
Josselin BrissetYvan JamillouxStephanie DumonteilGuillaume LadesMartin KillianMathieu Gerfaud-ValentinAnne LemaireTomasz ChroboczekEric LiozonGuillaume GondranPascal SèveJacques MonteilAnne-Laure FauchaisKim Heang LyPublished in: Journal of clinical medicine (2021)
While the diagnosis of adult-onset Still's disease (AOSD) involves the exclusion of differential diagnoses, the characteristics and value of 18F-Fluorodeoxyglucose (18F-FDG) Positron Emission Tomography coupled with CT (PET/CT) in the management of AOSD remain poorly known. Our retrospective study included patients from four centers, fulfilling Yamaguchi or Fautrel criteria, who underwent a PET/CT during an active AOSD. Thirty-five patients were included. At the time of PET/CT, the Yamaguchi criteria were met in 23 of 29 evaluable cases. PET/CT showed bone marrow (74.3%), lymph node (74.3%), and splenic (48.6%) FDG uptake. Despite arthralgia or arthritis in most patients, joints were rarely the sites of 18F-FDG accumulation. The spatial distribution of 18F-FDG uptake was nonspecific, and its intensity could be similar to malignant disease. Lymph node or bone marrow biopsy was performed after PET/CT in 20 patients (57.1%). The intensity of bone marrow; splenic and lymph node hypermetabolism appeared to be correlated with disease activity. Abnormal PET/CT in the cervical lymph nodes and age ≥ 60 years seemed to be predictive factors for monocyclic evolution. The clinical value of PET/CT is not in direct diagnosis; but as an aid in excluding differential diagnoses by searching for their scintigraphic features and guiding biopsy.
Keyphrases
- pet ct
- positron emission tomography
- lymph node
- bone marrow
- end stage renal disease
- computed tomography
- newly diagnosed
- ejection fraction
- peritoneal dialysis
- disease activity
- rheumatoid arthritis
- prognostic factors
- mesenchymal stem cells
- systemic lupus erythematosus
- magnetic resonance
- magnetic resonance imaging
- early stage
- squamous cell carcinoma
- patient reported
- high intensity
- patient reported outcomes
- contrast enhanced